

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011									
	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	27.7	122.8	(85-171.6)	Male	20	18.3	109.4	(66.8-168.9)
Female	7	9.7	71.9	(28.8-148.2)	Female	14	14.1	99.3	(54.3-166.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	5.4	186.3	(89.2-342.6)	Male	7	5.1	138.1	(55.3-284.6)
Female	1	4.4	nc	(nc-nc)	Female	5	4	125.7	(40.5-293.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	21	15.9	132.2	(81.8-202.1)
Female	115	106.2	108.3	(89.4-130)	Female	15	12.9	116.7	(65.3-192.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.8	nc	(nc-nc)	Male	9	12.2	74	(33.8-140.5)
<u>Colon / Rectum</u>					Female	5	5.2	96.8	(31.2-226)
Male	27	31.2	86.6	(57.1-126)	<u>Ovary</u>				
Female	29	30	96.8	(64.8-139.1)	Female	8	9.6	83.5	(36-164.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	7.7	nc	(nc-nc)	Male	10	9.2	109	(52.2-200.5)
Female	3	2	nc	(nc-nc)	Female	12	9.3	128.9	(66.5-225.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.2	nc	(nc-nc)	Male	101	108.8	92.8	(75.6-112.8)
Female	1	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	6.6	75.8	(24.4-177)
Male	20	15.2	131.8	(80.5-203.6)	Female	5	3.6	137.7	(44.4-321.3)
Female	7	8.5	81.9	(32.8-168.8)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.5	nc	(nc-nc)
Male	2	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.3	nc	(nc-nc)	Male	9	6.6	135.5	(61.8-257.2)
<u>Leukemia</u>					Female	21	19.7	106.6	(66-163)
Male	17	10.6	159.8	(93-255.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	7.6	105.3	(45.3-207.5)	Female	33	25	131.9	(90.8-185.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	8.8	102.1	(46.6-193.8)	Male	395	379.5	104.1	(94.1-114.9)
Female	0	2.9	nc	(nc-nc)	Female	386	361.3	106.8	(96.4-118)
<u>Lung and Bronchus</u>									
Male	52	51.7	100.6	(75.1-131.9)					
Female	58	52.3	111	(84.3-143.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;